GlobeNewsWire
02 Oct 2026, 11:30 UTC · 6h ago
Verdict
Headline takes no side. We score IFRX +0.60 across three claims — strongly bullish.
+0.60strongly bullish
More positive than 77% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish · 1 new · 2 priced in
InflaRx will present late-breaking pre-clinical data on izicopan for kidney disease models at Kidney Week 2026 on October 22.
Newpress release dated Oct 02, 2026
So whatThe data release on Oct 22 serves as a near-term catalyst that could trigger a valuation rerating for IFRX.
More positive than 79% of claims this week
Izicopan does not exhibit time-dependent inhibition of cytochrome P450 3A4 (CYP3A4), unlike the currently marketed C5aR inhibitor.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
Priced inno timing evidence provided for this specific finding
More positive than 66% of claims this week
First-in-human studies showed izicopan was well tolerated in single doses up to 240 mg and multiple doses up to 90 mg twice daily for 14 days.
Priced inno timing evidence provided for this specific finding
So whatThe wide safety margin supports the dosing flexibility needed for the upcoming Phase 2 trials in renal indications.
More positive than 53% of claims this week
Which stocks this story touches
More positive than 77% of ticker scores this week
The company was selected for a late-breaking poster session to present promising pre-clinical data on its drug izicopan.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
4h ago
+3.2%
Price agrees with the score
$1.76 vs $1.71 close before publication (Oct 1) · not market-adjusted
IFRX chart →
